Skip to main content

Advertisement

Table 1 Patient characteristics at the time of virological failure on initial ART (n = 84)

From: Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia

  n = 84
Age, median years (IQR) 37 (34–44)
Sex, n (%)  
Men 60 (71.4)
Women 24 (28.6)
Mode of HIV transmission, n (%)  
Injection drug use 52 (61.9)
Heterosexual contact 28 (33.3)
Male-to-male sex 2 (2.4)
Blood recipient 2 (2.4)
HCV infection, n (%)  
anti-HCV+ 45 (53.6)
anti-HCV- 39 (46.4)
Tuberculosis, n (%)  
History of TB 35 (41.7)
No history of TB 49 (58.3)
ART regimen at failure, n (%)  
Zidovudine + Lamivudine + Efavirenz 39 (46.4)
Zidovudine + Lamivudine + Nevirapine 14 (16.7)
Abacavir + Lamivudine + Efavirenz 17 (20.2)
Abacavir + Lamivudine + Nevirapine 3 (3.6)
Stavudine + Lamivudine + Efavirenz 7 (8.3)
Stavudine + Lamivudine + Nevirapine 2 (2.4)
Tenofovir + Emtricitabine + Efavirenz 2 (2.4)
6-month adherence prior to failure, n (%)  
<80% 36 (42.9)
80- < 100% 22 (26.2)
100% 26 (30.9)
Time to failure, median (IQR) 18 (12–34)
Viral load at failure, median copies/ml (IQR) 23600 (8365–126000)
Number of resistant mutations, median (IQR) 2 (1–4)
Drug class resistance, n (%)  
Single class (NRTI or NNRTI) 12 (14.3)
Dual class (NRTI + NNRTI) 72 (85.7)